Influence of uridine diphosphate (UDP)-glucuronosyltransferases and ABCC2 genetic polymorphisms on the pharmacokinetics of mycophenolic acid and its metabolites in Chinese renal transplant recipients

Xenobiotica

Volumn 38, Issue 11, 2008, Pages 1422-1436

  Zhang, W X ^a   Chen, B ^a   Jin, Z ^a   Yu, Z ^a   Wang, X ^a   Chen, H ^a   Mao, A ^a   Cai, W ^a,b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Pharmacy Department   (China)

Author keywords

ABCC2; Mycophenolic acid; Polymorphism; UGT1A9; UGT2B7

Indexed keywords

ACYL MYCOPHENOLIC ACID GLUCURONIDE; DRUG METABOLITE; GLUCURONOSYLTRANSFERASE; MULTIDRUG RESISTANCE PROTEIN 2; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID BETA D GLUCURONIDE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CHINESE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG METABOLISM; FEMALE; GENE FREQUENCY; GENETIC VARIABILITY; GRAFT RECIPIENT; HUMAN; KIDNEY GRAFT; MAJOR CLINICAL STUDY; MALE; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; ENZYME INHIBITORS; FEMALE; GENOTYPE; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HISTOCOMPATIBILITY TESTING; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; MYCOPHENOLIC ACID; POLYMORPHISM, GENETIC;

EID: 55549110397     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.1080/00498250802488585     Document Type: Article

References (35)

1. Allison AC, Eugui EM. 2000. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 47:85-118.
2. Baldelli S, Merlini S, Perico N, Nicastri A, Cortinovis M, Gotti E, Remuzzi G, Cattaneo D. 2007. C-440T/T-331C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation. Pharmacogenomics 8:1127-1141.
3. Basu NK, Kole L, Kubota S, Owens IS. 2004. Human UDP- glucuronosyltransferases show atypical metabolism of mycophenolic acid and inhibition by curcumin. Drug Metabolism and Disposition 32:768-773.
4. Bernard O, Guillemette C. 2004. The main role of UGT1A9 in the hepatic metabolism of mycophenolic acid and the effects of naturally occurring variants. Drug Metabolism and Disposition 32:775-778.
5. Bernard O, Tojcic J, Journault K, Perusse L, Guillemette C. 2006. Influence of nonsynonymous polymorphisms of UGT1A8 and UGT2B7 metabolizing enzymes on the formation of phenolic and acyl glucuronides of mycophenolic acid. Drug Metabolism and Disposition 34:1539-1545.
6. Bhasker CR, McKinnon W, Stone A, Lo AC, Kubota T, Ishizaki T, Miners JO. 2000. Genetic polymorphism of UDP-glucuronosyltransferase 2B7 (UGT2B7) at amino acid 268: Ethnic diversity of alleles and potential clinical significance. Pharmacogenetics 10:679-685.
7. Bullingham RE, Nicholls AJ, Kamm BR. 1998. Clinical pharmacokinetics of mycophenolate mofetil. Clinical Pharmacokinetics 34:429-455.
8. Carlini LE, Meropol NJ, Bever J, Andria ML, Hill T, Gold P, Rogatko A, Wang H, Blanchard RL. 2005. UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clinical Cancer Research 11:1226-1236.
9. Chen B, Zhang WX, Yu ZC, Cai WM. 2007. Determination of mycophenolic acid (MPA) and its acyl and phenol glucuronide metabolites simultaneously in human plasma by a simplified HPLC method. Analytical Letters 40:2465-2475.
10. Coffman BL, Kearney WR, Green MD, Lowery RG, Tephly TR. 2001. Analysis of opioid binding to UDPglucuronosyltransferase 2B7 fusion proteins using nuclear magnetic resonance spectroscopy. Molecular Pharmacology 59:1464-1469.
11. Djebli N, Picard N, Rerolle JP, Le Meur Y, Marquet P. 2007. Influence of the UGT2B7 promoter region and exon 2 polymorphisms and comedications on acyl-MPAG production in vitro and in adult renal transplant patients. Pharmacogenetics and Genomics 17:321-330.
12. Ensom MH, Partovi N, Decarie D, Dumont RJ, Fradet G, Levy RD. 2002. Pharmacokinetics and protein binding of mycophenolic acid in stable lung transplant recipients. Therapeutic Drug Monitoring 24:310-314.
13. Girard H, Court MH, Bernard O, Fortier LC, Villeneuve L, Hao Q, Greenblatt DJ, Von Moltke LL, Perussed L, Guillemette C. 2004. Identification of common polymorphisms in the promoter of the UGT1A9 gene: Evidence that UGT1A9 protein and activity levels are strongly genetically controlled in the liver. Pharmacogenetics 14:501-515.
14. Hesselink DA, Van Hest RM, Mathot RA, Bonthuis F, Weimar W, De Bruin RW, Van Gelder T. 2005. Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. American Journal of Transplantation 5:987-994.
15. Hirota T, Ieiri I, Takane H, Sano H, Kawamoto K, Aono H, Yamasaki A, Takeuchi H, Masada M, Shimizu E, et al. 2003. Sequence variability and candidate gene analysis in two cancer patients with complex clinical outcomes during morphine therapy. Drug Metabolism and Disposition 31:677-680.
16. Innocenti F, Liu W, Chen P, Desai AA, Das S, Ratain MJ. 2005. Haplotypes of variants in the UDP-glucuronosyltransferase1A9 and 1A1 genes. Pharmacogenetics and Genomics 15:295-301.
17. Ito S, Ieiri I, Tanabe M, Suzuki A, Higuchi S, Otsubo K. 2001. Polymorphism of the ABC transporter genes, MDR1, MRP1 and/cMOAT, in healthy Japanese subjects. Pharmacogenetics 11:175-184.
18. Kagaya H, Inoue K, Miura M, Satoh S, Saito M, Tada H, Habuchi T, Suzuki T. 2007. Influence of UGT1A8 and UGT2B7 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. European Journal of Clinical Pharmacology 63:279-288.
19. Kobayashi M, Saitoh H, Kobayashi M, Tadano K, Takahashi Y, Hirano T. 2004. Cyclosporin A, but not tacrolimus, inhibits the biliary excretion of mycophenolic acid glucuronide possibly mediated by multidrug resistance-associated protein 2 in rats. Journal of Pharmacology and Experimental Therapeutics 309:1029-1035.
20. Kuypers DR, Claes K, Evenepoel P, Maes B, Coosemans W, Pirenne J, Vanrenterghem Y. 2003a. Long-term changes in mycophenolic acid exposure in combination with tacrolimus and corticosteroids are dose dependent and not reflected by trough plasma concentration: A prospective study in 100 de novo renal allograft recipients. Journal of Clinical Pharmacology 43:866-880.
21. Kuypers DR, Naesens M, Vermeire S, Vanrenterghem Y. 2005. The impact of uridine diphosphateglucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients. Clinical Pharmacology and Therapeutics 78:351-361.
22. Kuypers DR, Vanrenterghem Y, Squifflet JP, Mourad M, Abramowicz D, Oellerich M, Armstrong V, Shipkova M, Daems J. 2003b. Twelve-month evaluation of the clinical pharmacokinetics of total and free mycophenolic acid and its glucuronide metabolites in renal allograft recipients on low dose tacrolimus in combination with mycophenolate mofetil. Therapeutic Drug Monitoring 25:609-622.
23. Lévesque E, Delage R, Benoit-Biancamano MO, Caron P, Bernard O, Couture F, Guillemette C. 2007. The impact of UGT1A8, UGT1A9, and UGT2B7 genetic polymorphisms on the pharmacokinetic profile of mycophenolic acid after a single oral dose in healthy volunteers. Clinical Pharmacology and Therapeutics 81:392-400.
24. Naesens M, Kuypers DR, Verbeke K, Vanrenterghem Y. 2006. Multidrug resistance protein 2 genetic polymorphisms influence mycophenolic acid exposure in renal allograft recipients. Transplantation 82:1074-1084.
25. Rau T, Erney B, Gores R, Eschenhagen T, Beck J, Langer T. 2006. High-dose methotrexate in pediatric acute lymphoblastic leukemia: Impact of ABCC2 polymorphisms on plasma concentrations. Clinical Pharmacology and Therapeutics 80:468-476.
26. Saeki M, Saito Y, Jinno H, Sai K, Ozawa S, Kurose K, Kaniwa N, Komamura K, Kotake T, Morishita H, et al. 2006. Haplotype structures of the UGT1A gene complex in a Japanese population. Pharmacogenomics Journal 6:63-75.
27. Shaw LM, Kaplan B, DeNofrio D, Korecka M, Brayman KL. 2000. Pharmacokinetics and concentration-control investigations of mycophenolic acid in adults after transplantation. Therapeutic Drug Monitoring 22:14-19.
28. Shaw LM, Korecka M, Venkataramanan R, Goldberg L, Bloom R, Brayman KL. 2003. Mycophenolic acid pharmacodynamics and pharmacokinetics provide a basis for rational monitoring strategies. American Journal of Transplantation 3:534-542.
29. Shipkova M, Strassburg CP, Braun F, Streit F, Gröne HJ, Armstrong VW, Tukey RH, Oellerich M, Wieland E. 2001a. Glucuronide and glucoside conjugation of mycophenolic acid by human liver, kidney and intestinal microsomes. British Journal of Pharmacology 132:1027-1034.
30. Shipkova M, Wieland E, Schütz E, Wiese C, Niedmann PD, Oellerich M, Armstrong VW. 2001b. The acyl glucuronide metabolite of mycophenolic acid inhibits the proliferation of human mononuclear leukocytes. Transplant Proceeding 33:1080-1081.
31. Staatz CE, Tett SE. 2007. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clinical Pharmacokinetics 46:13-58.
32. Suzuki H, Sugiyama Y. 2002. Single nucleotide polymorphisms in multidrug resistance associated protein 2 (/ABCC2): Its impact on drug disposition. Advanced Drug Delivery Reviews 54:1311-1331.
33. Van Gelder T, Klupp J, Barten MJ, Christians U, Morris RE. 2001. Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Therapeutic Drug Monitoring 23:119-128.
34. Yamanaka H, Nakajima M, Katoh M, Hara Y, Tachibana O, Yamashita J, McLeod HL, Yokoi T. 2004. A novel polymorphism in the promoter region of human UGT1A9 gene (UGT1A9*22) and its effects on the transcriptional activity. Pharmacogenetics 14:329-332.
35. Zhang W, Liu W, Innocenti F, Ratain MJ. 2007. Searching for tissue-specific expression pattern-linked nucleotides of UGT1A isoforms. Public Library of Science ONE 2:e396.